How can pharmaceutical companies prevent commercial bribery risks? Compliance guidelines are here

News Anti-Bribery & Corruption Guidance

Date: 15th Jan, 2025 Source: State Administration for Market Regulation (SAMR) Country: China Original Source

Brief

"On December 20, 2023, the Market Supervision Administration released a new compliance guideline titled 《医药企业防范商业贿赂风险合规指引》 (_Guidance on Preventing Commercial Bribery Risks for Pharmaceutical Enterprises). The guideline aims to strengthen compliance in the pharmaceutical industry, specifically covering 9 scenarios of commercial bribery risks and providing guidance on risk identification, prevention, and mitigation. This new measure is expected to enhance regulatory efficiency and promote a clean and transparent market order."

This content is restricted.

Highlights content goes here...

This content is restricted.

State Administration for Market Regulation (SAMR)

RADA.AI

Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?

Suggested

How can pharmaceutical companies prevent commercial bribery risks? Compliance guidelines are here

Brief

State Administration for Market Regulation (SAMR)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.

How can pharmaceutical companies prevent commercial bribery risks? Compliance guidelines are here

Brief

State Administration for Market Regulation (SAMR)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify OTP

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.